STATE OF OKLAHOMA

2nd Session of the 60th Legislature (2026)

SENATE BILL 1344 By: Rosino

AS INTRODUCED

An Act relating to prescription drugs; creating the Insulin Access and Affordability Program for specified purpose; directing the State Department of Health to provide certain financial support; requiring certain agreement with nonprofit pharmaceutical manufacturer; describing agreement; providing for codification; providing an effective date; and declaring an emergency.

BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:

SECTION 1. NEW LAW A new section of law to be codified in the Oklahoma Statutes as Section 1-271 of Title 63, unless there is created a duplication in numbering, reads as follows:

A. There is hereby created the Insulin Access and Affordability Program, which shall be administered by the State Department of Health for the purpose of increasing patient access to affordable insulin in this state, increasing marketplace competition, and addressing shortages in the market for generic insulin.

B. The Department shall, with funds appropriated by the Legislature, provide financial support to a nonprofit pharmaceutical manufacturer that is currently developing a fast-acting biosimilar insulin.

C. Prior to disbursement of any funds, the Department shall enter into a memorandum of understanding (MOU) with the nonprofit pharmaceutical manufacturer and the manufacturer shall demonstrate a match of non-state funds equal to the amount provided under this section. The MOU shall include:

1. A commitment by the manufacturer to produce a fast-acting biosimilar insulin at a low net cost without rebates except as required by law;

2. Estimated savings from the purchase of low-cost, fast-acting biosimilar insulin including, but not limited to, the estimated savings to residents of this state and public and private payors from the availability of low-cost, fast-acting biosimilar insulin;

3. Provisions related to the repayment of the funds provided under this section should the manufacturer fail to produce and distribute a low-cost, fast-acting biosimilar insulin; and

4. Annual reporting by the manufacturer to the Department on the development of the fast-acting biosimilar insulin.

SECTION 2. This act shall become effective July 1, 2026.

SECTION 3. It being immediately necessary for the preservation of the public peace, health or safety, an emergency is hereby

declared to exist, by reason whereof this act shall take effect and be in full force from and after its passage and approval.

60-2-2896 DC 12/30/2025 10:13:39 AM